Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

For decades, Alzheimer's research has focused on examining amyloid plaques in the brain and prescribing antibody therapeutics that remove the plaques to slow cognitive decline in patients.

A new study suggests that Medicare could save up to $366 million annually by introducing a new vial size for Alzheimer's drug lecanemab, which is currently only available in single-use, 500- and ...

Looking to purchase Modafinil in the USA in 2024? This review provides information about reliable vendors for ordering ...

Want to get free Modafinil samples without a prescription? In this guide, you will discover the best places to order a free ...

Prescription digital therapeutics for mental health have the potential to increase patient access to care, but major barriers ...

Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown ...

Cobenfy's journey from the lab through regulatory approval is a case study in how America's world-class scientists work to ...

A recent study published in Genomic Psychiatry has unveiled a promising new therapy that may help improve memory and reduce ...

An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown ...